Coronary disease in type 1 diabetes: Causal contiguity and clinical implications

Diabetes Care

Volumn 26, Issue 5, 2003, Pages 1629-1630

  Sobel, Burton E ^a,b  

^a UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

^b University of Vermont Colchester Research Facility   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PLASMINOGEN ACTIVATOR INHIBITOR 1;

CARDIOVASCULAR DISEASE; CORONARY ARTERY DISEASE; EDITORIAL; FIBRINOLYSIS; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RESISTANCE; MICROANGIOPATHY;

CORONARY DISEASE; DIABETES MELLITUS, TYPE 1; DIABETIC ANGIOPATHIES; HUMANS; INSULIN RESISTANCE;

EID: 0041667822     PISSN: 01495992     EISSN: None     Source Type: Journal    
DOI: 10.2337/diacare.26.5.1629     Document Type: Editorial

References (8)

1. Orchard TJ, Olson JC, Erbey JR, Williams K, Forrest KY-Z, Smithline Kinder L, Ellis D, Becker DJ: Insulin resistance-related factors, but not glycemia, predict coronary artery disease in type 1 diabetes: 10-year follow-up data from the Pittsburgh Epidemiology of Diabetes Complications study. Diabetes Care 26:1374-1379, 2003
2. Schneider DJ, Sobel BE: The coagulation and fibrinolytic systems, diabetes, and the heart: therapeutic implications for patients with type 2 diabetes. In Medical Management of Diabetes and Heart Disease. New York, Marcel Dekker, 2002, p. 105-115
3. Lebovitz HE: Types of diabetes and their implications regarding heart and vascular disease. In Medical Management of Diabetes and Heart Disease. New York, Marcel Dekker, 2002, p. 9-33
4. Kolvisto VA, Stevens LK, Mattock M, Ebeling P, Muggeo M, Stephenson J, Idzior-Walus B, the EURODIAB IDDM Complications Study Group: Cardiovascular disease and its risk factors in IDDM in Europe. Diabetes Care 19:689-697, 1996
5. Reaven GM: Insulin resistance and human disease: a short history. J Basic Clin Physiol Pharmacol 9:387-406, 1998
6. Despres JP, Lamarche B, Mauriege P, Cantin B, Dagenais GR, Moorjani S, Lupien PJ: Hyperinsulinemia as an independent risk factor for ischemic heart disease. N Engl J Med 334:952-957, 1996
7. Sobel BE, Frye R, Detre KM: Burgeoning dilemmas in the management of diabetes and cardiovascular disease: rationale for the BARI 2D trial. Circulation 107:636-642, 2003
8. Sobel BE: Increased plasminogen activator inhibitor-1 and vasculopathy: a reconcilable paradox. Circulation 99:2496-2498, 1999